Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 4
2013 3
2014 5
2015 7
2016 8
2017 2
2018 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Cancer drug resistance: an evolving paradigm.
Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Holohan C, et al. Nat Rev Cancer. 2013 Oct;13(10):714-26. doi: 10.1038/nrc3599. Nat Rev Cancer. 2013. PMID: 24060863 Review.
Overcoming Resistance to Targeted Therapies in Cancer.
Redmond KL, Papafili A, Lawler M, Van Schaeybroeck S. Redmond KL, et al. Semin Oncol. 2015 Dec;42(6):896-908. doi: 10.1053/j.seminoncol.2015.09.028. Epub 2015 Sep 25. Semin Oncol. 2015. PMID: 26615134 Review.
Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.
Bradley CA, Salto-Tellez M, Laurent-Puig P, Bardelli A, Rolfo C, Tabernero J, Khawaja HA, Lawler M, Johnston PG, Van Schaeybroeck S; MErCuRIC consortium. Bradley CA, et al. Nat Rev Clin Oncol. 2018 Jan 23;15(3):150. doi: 10.1038/nrclinonc.2018.13. Online ahead of print. Nat Rev Clin Oncol. 2018. PMID: 29358775
Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program.
Lawler M, Gavin A, Salto-Tellez M, Kennedy RD, Van Schaeybroeck S, Wilson RH, Harkin DP, Grayson M, Boyd RE, Hamilton PW, McArt DG, James J, Robson T, Ladner RD, Prise KM, O'Sullivan JM, Harrison T, Murray L, Johnston PG, Waugh DJ. Lawler M, et al. Cancer. 2016 Mar 1;122(5):664-73. doi: 10.1002/cncr.29814. Epub 2015 Dec 22. Cancer. 2016. PMID: 26695702 Free PMC article.
ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer.
Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG. Van Schaeybroeck S, et al. Cell Rep. 2014 Jun 26;7(6):1940-55. doi: 10.1016/j.celrep.2014.05.032. Epub 2014 Jun 12. Cell Rep. 2014. PMID: 24931611 Free article.
26 results